Gene · 10112
KIF20A: kinesin family member 20A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KIF20A: kinesin family member 20A. Genes, record 10112. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10112
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O95235 | Kinesin-like protein KIF20A | 890 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents98
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 50835 | O95235 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11209 | O95235 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 11672 | O95235 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5916 | O95235 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 11672 | O95235 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11209 | O95235 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5916 | O95235 | Espacenet |
| EP 4487869 A2 | 2025-01-08 | 254 | O95235 | Espacenet |
| KR 1020240027895 A | 2024-03-04 | 444 | O95235 | Espacenet |
| JP 2023536814 A | 2023-08-30 | 7192 | O95235 | Espacenet |
1 to 10 of 98
See all 98 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants588
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KIF20A papers | Newest fiscal year |
|---|---|---|---|
| P30CA051008 | Georgetown University Lombardi Comprehensive Cancer Center Support Grant | 4 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| R35GM119455 | Mechanisms of Phosphorylation Signaling by Phosphoprotein Phosphatases | 3 | 2025 |
| T32CA009686 | Training Grant In Tumor Biology | 3 | 2025 |
| I01BX002773 | A Novel Drug Target for Aggressive Prostate Cancer | 2 | 2025 |
| P20GM113132 | The Institute for Biomolecular Targeting | 2 | 2025 |
| P30CA013148 | Comprehensive Cancer Center Support Grant | 2 | 2025 |
| P30CA016042 | Cancer Center Support Grant | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 588Source NIH's project files
See all 588 nih grantsPapers1,613
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ionizing radiation induces senescence of dermal papilla cells through inhibiting the FOXM1-KIF20A pathway. | Genes Dis | 2027 | 42733528 | PubTator, text mining | PubMed |
| Identification of functional genes and immune cell infiltration analysis in liposarcoma. | PLoS One | 2026 | 42726806 | PubTator, text mining | PubMed |
| Microplastics and nanoplastics-related genes signature predicts prognosis in pancreatic ductal adenocarcinoma and functional validation of interleukin 1 alpha. | Transl Cancer Res | 2026 | 42724844 | PubTator, text mining | PubMed |
| Identification of a cholesterol metabolism-related signature based on KIF20A and NDC80 for prognostic stratification and immunotherapy prediction in hepatocellular carcinoma. | Cancer Biomark | 2026 | 42685023 | PubTator, text mining | PubMed |
| MicroRNA Signatures of Fulvestrant-Treated Luminal Breast Cancer Cells: Identification of Therapeutic Targets Regulated by miR-374b-5p. | Int J Mol Sci | 2026 | 42589442 | PubTator, text mining | PubMed |
| Kinesins in Bladder Cancer: Integrating Molecular Mechanisms and Treatment Approaches. | Cell Biol Int | 2026 | 42529891 | PubTator, text mining | PubMed |
| Unveiling immune-related gene signatures in triple negative breast cancer through integrated transcriptomic analysis. | Biomedicine (Taipei) | 2026 | 42483440 | PubTator, text mining | PubMed |
| Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/progenitor cells. | Stem Cell Reports | 2026 | 42462712 | PubTator, text mining | PubMed |
| KIAA1429 promotes gallbladder cancer progression through m6A-dependent post-transcriptional modification of KIF20A. | Sci Rep | 2026 | 42437826 | PubTator, text mining | PubMed |
| Large-scale transcriptome analysis reveals KIF20A as a novel indicator of cisplatin resistance in high-grade serous ovarian cancer. | J Ovarian Res | 2026 | 42426841 | PubTator, text mining | PubMed |
1 to 10 of 1,613
See all 1,613 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10112
GET https://conductscience.org/api/genes/v1/10112/patents?page=2